Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Is Pfizer Inc. PFE the Undervalued Defensive Stock for 2025?

January 22, 2025
Pfizer Inc. (NYSE:PFE) has long been one of the major players in the pharmaceutical industry. With a history dating back to 1849, Pfizer has established itself as a global leader in the development and production of innovative medicines.

However, despite its strong position in the market, Pfizer's stock has been undervalued in recent years. This presents a unique opportunity for investors looking for a defensive stock to add to their portfolios.

According to Stocks Prognosis, a leading financial forecasting company, Pfizer is projected to experience significant growth in the coming years. The company's robust pipeline of promising new drugs, combined with its strong presence in key markets, is expected to drive revenue and earnings growth.

In addition, Pfizer has a solid dividend track record, making it an attractive choice for income-focused investors. The company has consistently raised its dividend for several years, and its current yield is above the industry average.

Furthermore, Pfizer's diversified portfolio of products and its ongoing efforts in research and development ensure its ability to adapt to changing market trends and regulatory environments.

Despite facing competition from other pharmaceutical giants, Pfizer has a distinct advantage. Its strong brand recognition, established relationships with healthcare providers, and global reach provide a competitive edge that sets it apart from its rivals.

Considering these factors, experts at Stocks Prognosis recommend investors to consider buying Pfizer Inc. (NYSE:PFE) shares. The undervalued stock, combined with the company's solid fundamentals and growth potential, make it an attractive investment for the long term.

Investors who are interested in taking advantage of the potential growth of Pfizer Inc. (NYSE:PFE) should consult professionals at Stocks Prognosis for expert advice and guidance on the forecasted movement of the company's shares.
If you want to leave a comment, then you need Login or Register





Other data for PFE

Related data

PFEAugust 21, 2025PFIZER INC. Stock Hits Price Target Forecast with 6.7% Profit: QuantWave Analysis  ~1 min.

PFIZER INC. (PFE) investors celebrated as the stock reached the price target forecast set by QuantWave on August 21st, 2025, resulting in a 6.7% profit....


PFEAugust 21, 2025PFIZER INC. Hits Price Target Forecast with 7.31% Profit Achieved  ~1 min.

QuantWave, the automated forecasting platform, successfully predicted the price movement of PFIZER INC.'s stock with a 7.31% profit realized....


PFEAugust 21, 2025PFIZER INC. Achieves Forecast Price Target with 9.1% Profit on QuantWave  ~1 min.

Pfizer Inc. stock has successfully reached the forecasted price target on QuantWave's automated forecasting platform, resulting in a profit of 9.1%....


PFEJuly 10, 2025PFIZER INC. Stock Hits Price Target Forecast With 10.06% Profit, Boosting QuantWave's Analytics  ~1 min.

On May 5, 2025, QuantWave, the automated forecasting platform, issued a long signal for PFIZER INC. stock when it was trading at $23.03....


PFEJuly 10, 2025PFIZER INC. Hits Price Target Forecast with 8.56% Profit Achieved  ~1 min.

On May 2, 2025, QuantWave issued a price target forecast for PFIZER INC. with a signal to go long at $23.34. The predicted direction was realized on July 10, 2025, when the stock reached $25....


PFEJuly 10, 2025PFIZER INC. Hits Price Target Forecast with 6.57% Profit: A Success Story for QuantWave Analytics  ~2 min.

On June 27, 2025, QuantWave, the automated forecasting platform, released a price target forecast for PFIZER INC., signaling a long position with the stock trading at $23.78....


PFEJuly 10, 2025PFIZER INC. Stock Hits Forecast Price Target with 6.27% Profit: A Success Story for QuantWave  ~2 min.

In a recent market development, PFIZER INC. stock has successfully reached the price target forecasted by QuantWave, resulting in a profit of 6.27%....


PFEJuly 10, 2025PFIZER INC. Hits Price Target with 6.35% Profit: A Success Story for QuantWave Forecasting  ~1 min.

PFIZER INC. has recently hit the price target forecasted by QuantWave, achieving a profit of 6.35% for investors. The forecast signal was generated on June 26, 2025, with a price of 23.83 $....


PFEJuly 10, 2025PFIZER INC. Hits Price Target Forecast with 6.09% Profit: QuantWave Analysis  ~1 min.

On June 10, 2025, QuantWave, the automated forecasting platform, issued a long signal for PFIZER INC. (PFE) when the stock was trading at $23.89. Fast forward to July 10, 2025, and the price target of $25....


PFEJuly 10, 2025PFIZER INC. Stock Hits Price Target Forecast with 6.05% Profit  ~1 min.

On June 24, 2025, QuantWave issued a long signal for PFIZER INC. stock when it was trading at $23.9. Analysts predicted a target price of $25....


AZNDecember 9, 2024Is AstraZeneca PLC AZN the Most Profitable Pharmaceutical Stock Right Now?  ~2 min.

AstraZeneca PLC (AZN) is emerging as one of the most profitable pharmaceutical stocks in the market....


MRKJanuary 1, 2025Merck & Co., Inc. Shows Resilience With Strong Fundamentals  ~2 min.

Despite recent market weakness, pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) remains a strong investment opportunity....


ABTJanuary 2, 2025Abbott Laboratories' Fundamental Strengths Signal Future Market Correction: Stocks Prognosis  ~1 min.

Abbott Laboratories, a global healthcare company, has lately witnessed a decline in its stock performance....


GSKJanuary 25, 2025Is GSK plc GSK an Undervalued Defensive Stock for 2025?  ~2 min.

GSK plc (NYSE: GSK) has been gaining attention as a potential undervalued defensive stock for investors looking towards 2025....


ABTDecember 13, 2024Abbott Laboratories Continues to Impress Investors with Solid Dividends and Growth  ~2 min.

Abbott Laboratories (NYSE: ABT) has emerged as one of the best Dividend Kings in the market, offering safe dividend growth for long-term investors....